USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Genprex Inc(GNPX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

GNPX
GNPX
Genprex Inc
At close Nov 13 at 4:00 PM ET (Korea 11/14 06:00)
$2.08
-0.13 ▼ -5.88%
Nov 13 at 4:00 PM ET (Korea 11/14 06:00)
$2.08
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -158.75Insider Own ⓘ 0.21%Shs Outstand ⓘ 0.8MPerf Week ⓘ 0.48%
Market Cap ⓘ 0.00BForward P/E ⓘ -EPS next Y ⓘ -Insider Trans ⓘ -Shs Float ⓘ 0.8MPerf Month ⓘ -9.17%
Enterprise Value ⓘ -0.01BPEG ⓘ -EPS next Q ⓘ -Inst Own ⓘ 1.24%Short Float ⓘ 15.03%Perf Quarter ⓘ -53.52%
Income ⓘ -0.02BP/S ⓘ -EPS this Y ⓘ -Inst Trans ⓘ 1.22%Short Ratio ⓘ 0.51Perf Half Y ⓘ -88.61%
Sales ⓘ 0.00BP/B ⓘ 0.07EPS next 5Y ⓘ -ROA ⓘ -157.4%Short Interest ⓘ 0.12MPerf YTD ⓘ -94.6%
Book/sh ⓘ 29.23P/C ⓘ 0.11EPS past 3/5Y ⓘ 74% 55.62%ROE ⓘ -203.86%52W High ⓘ -97.98% ($103.16)Perf Year ⓘ -97.72%
Cash/sh ⓘ 18.5P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -111.51%52W Low ⓘ 21.64% ($1.71)Perf 3Y ⓘ -99.98%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 93.08%Gross Margin ⓘ -Volatility(W/M) ⓘ 7.69% 9.61%Perf 5Y ⓘ -100%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.21Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 6.77EPS Q/Q ⓘ 94.96%Profit Margin ⓘ -RSI (14) ⓘ 40.72Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 6.77Sales Q/Q ⓘ -SMA20 ⓘ -0.14% ($2.08)Beta ⓘ -0.99Target Price ⓘ $8250
Payout ⓘ -Debt/Eq ⓘ 0Earnings ⓘ -SMA50 ⓘ -21.57% ($2.65)Rel Volume ⓘ 0.05Prev Close ⓘ $2.21
Employees ⓘ 13LT Debt/Eq ⓘ 0EPS/Sales Surpr. ⓘ -SMA200 ⓘ -88.15% ($17.55)Avg Volume(3M) ⓘ 0.24MPrice ⓘ $2.08
IPO ⓘ 2018/3/29Option/Short ⓘ No/YesTrades ⓘ 261Volume ⓘ 11,534Change ⓘ -5.88%
Company
GNPX GNPXGenprex Inc | NASD | Biotechnology Deep dive

🧬 Genprex () is a US clinical-stage biotech developing gene therapies for cancer and diabetes treatment. Its lead candidate, Reqorsa® (quaratusugene ozeplasmid), is a non-viral gene therapy based on the TUSC2 tumor suppressor gene, with ongoing lung cancer clinical trials (Acclaim-1 and Acclaim-3) in combination with the EGFR-targeted therapy Tagrisso and the immunotherapy Tecentriq.

Quote

Over the past 1 year, on the lower side

98% below its 1-year high.

Now $2.08
52w low$1.7152w high$103.16
52W Range0%
Volume ⓘ 11,534

Traded less than usual. That is 5% of its average volume.

D
Overall · many cautions
We judged 4 of the 8 questions below. 3 need caution.
No data for growth, valuation, outlook, dividends, or not applicable.
ETFs holding this stock 1 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #580 of 598 in the industry

Based on market cap of $2M.

FAQ

FAQ

What kind of company is GNPX?

GNPX belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of GNPX?

The market cap of GNPX is approximately $2M, ranking 5,805 within its sector.

What is the 52-week high and low for GNPX?

GNPX has recorded a 52-week high of $103.16 and a low of $1.71.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels